OssDsign announces the establishment of a U.S. Strategic Surgeon Advisory Board
Uppsala, June 7, 2022. OssDsign AB (publ.) today announces that the company has established a Strategic Surgeon Advisory Board (SSAB) in the U.S. The primary objective of the SSAB is to assist the company with guidance and advice on strategic matters.
The SSAB will consist of seven leading U.S. neurosurgical and orthopaedic spinal surgeons who will advise the company on matters related to the future direction and priorities for the company such as new product development, regulatory pathways, clinical programs and similar areas that carry strategic importance.
OssDsign’s SSAB will initially be chaired by Peter Whang, M.D., F.A.C.S., F.A.A.O.S, Associate Professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine.
“I’m delighted to work with OssDsign. The technology that OssDsign is bringing to market is very novel and I expect it to be very beneficial for my patients. I am excited to be serving as an advisor to the company moving forward,” says Dr. Whang.
“The opportunity to interact with top U.S. Key Opinion Leaders is important for the future of the company. I am extremely proud that we have been able to attract such talented and renowned surgeons who are deeply knowledgeable about the Spine and Orthobiologics market. I look forward to working closely with Dr. Whang as well as our other surgeon advisors in the SSAB,” says Morten Henneveld, CEO of OssDsign.
Dr. Whang is a U.S. board-certified, fellowship-trained, surgeon who specializes in treating diseases of the cervical, thoracic and lumbar regions of the spine and is particularly interested in novel spinal technologies. Dr. Whang is currently an Associate Professor at the Department of Orthopaedics and Rehabilitation at Yale University School of Medicine. Dr. Whang received his undergraduate degree in biochemistry from Harvard University, MA, and his medical degree from the Duke University School of Medicine, NC. He completed his residency in orthopaedic surgery at the University of California, Los Angeles, CA, and received his specialized fellowship training in orthopaedic and neurosurgical spinal surgery at the Rothman Institute at Thomas Jefferson University, Philadelphia, PA.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: